Haupenthal Frederik, Doberer Konstantin, Kapps Sebastian, Kläger Johannes, Bauernfeind Florian, Denhaerynck Kris, Kainz Alexander, De Geest Sabina, Bond Gregor
Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Austria.
Department of Pathology, Medical University of Vienna, Austria.
Nephrol Dial Transplant. 2025 Apr 28. doi: 10.1093/ndt/gfaf078.
After kidney transplantation adherence to immunosuppressive medication is crucial for graft survival and its assessment requires valid measurements. The Basel-Assessment-of-Adherence-to-Immunosuppressive-Medications-Scale (BAASIS) is a validated self-report tool to detect non-adherence, however its ability to predict clinically relevant outcomes remains to be established.
In this prospective cohort study including 226 consecutive kidney graft recipients transplanted at the Medical University of Vienna between 2018 and 2019 the adherence towards immunosuppressive medication was monitored for 2 years after transplantation. The BAASIS was applied at the first outpatient visit and at months 3, 6, 9, 12, and 24 post-transplant to assess the implementation and persistence phase of adherence. Non-adherence was defined by any positive response to one of the BAASIS-items. The primary endpoint was biopsy-proven allograft rejection defined by the BANFF meeting report during a maximum follow-up of 4 years.
Of the total study cohort (median age 56 years [IQR 46-63], 75 [33%] female), 125 recipients (55%) reported non-adherence at least once. Self-reported non-adherence increased within the first three months from 11% to 31% and remained between 27% and 32% at month 6 to 24 post-transplant. Non-adherent recipients experienced more allograft rejections than adherent patients (24%, n=30 vs. 7%, n = 7; P < 0.001) during a median follow-up of 3.7 years (IQR 1.0-4.0). Using a time-dependent Cox regression model, the adjusted hazard ratio for allograft rejection associated with previously reported non-adherence was 2.90 (95% CI 1.51-5.58; P = 0.001) accounting for recipient sex, age at transplantation and history of previous transplantation.
Our findings support the clinical value of the BAASIS. Its implementation into routine post-transplant care may facilitate the identification of clinically relevant medication non-adherence, enabling timely interventions.
肾移植后坚持服用免疫抑制药物对移植物存活至关重要,其评估需要有效的测量方法。巴塞尔免疫抑制药物依从性评估量表(BAASIS)是一种经过验证的自我报告工具,用于检测不依从情况,但其预测临床相关结果的能力仍有待确定。
在这项前瞻性队列研究中,纳入了2018年至2019年在维也纳医科大学连续接受移植的226例肾移植受者,在移植后对免疫抑制药物的依从性进行了2年的监测。在首次门诊就诊时以及移植后第3、6、9、12和24个月应用BAASIS,以评估依从性的实施和持续阶段。对BAASIS项目之一的任何阳性反应定义为不依从。主要终点是在最长4年的随访期间,根据班夫会议报告定义的经活检证实的同种异体移植物排斥反应。
在整个研究队列中(中位年龄56岁[四分位间距46 - 63岁],75例[33%]为女性),125例受者(55%)至少报告过一次不依从。自我报告的不依从在最初三个月内从11%增加到31%,在移植后第6至24个月保持在27%至32%之间。在中位随访3.7年(四分位间距1.0 - 4.0)期间,不依从的受者比依从的患者经历了更多的同种异体移植物排斥反应(24%,n = 30 vs. 7%,n = 7;P < 0.001)。使用时间依赖性Cox回归模型,在考虑受者性别、移植时年龄和既往移植史的情况下,与先前报告的不依从相关的同种异体移植物排斥反应的调整后风险比为2.90(95%置信区间1.51 - 5.58;P = 0.001)。
我们的研究结果支持BAASIS的临床价值。将其应用于常规移植后护理可能有助于识别临床相关的药物不依从情况,从而能够及时进行干预。